Archived explainer. For the current picture see today's LQDA page.
Why Is LIQUIDIA CORP (LQDA) Stock Up Today?
LIQUIDIA CORP (LQDA) is up +6.41% in the latest session. Our newswire has captured 15 stories on LQDA across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Liquidia Corp (LQDA) shares rose 6.41% to $50.94, driven by a strong third-quarter earnings report and a wave of price target increases from major investment banks. The stock outperformed following the announcement of record October shipments and a widening prescriber base, which followed a costly legal settlement.
What Happened
Liquidia reported Q3 2026 net product sales of $222.7 million, a 31% increase year over year. Adjusted earnings per share came in at $1.71, significantly exceeding the consensus estimate of $0.96. Management deferred 2027 guidance until early January to better track post-settlement demand. The company plans to complete enrollment for its PH-ILD trial in 2028, with a target NDA submission for L606 in 2029.
Analysts responded positively to the results. BTIG raised its price target to $87 from $70, citing strong demand. Needham increased its target to $66 from $58, while Jefferies raised its target to $62 on revenue growth. The company is scheduled to present at the 2026 Jefferies Global Healthcare Conference.
What The Data Shows
The stock opened at $47.87 and reached a session high of $51.00 at 3:15 PM ET. Volume was 1.4 million shares, which is 0.5 times the 3-month daily average. The company has a market capitalization of $4.0 billion and a P/E ratio of 32.4. Trailing twelve-month revenue growth stands at 2233.6%, with a net margin of 30.7%. The 52-week range is $22.31 to $93.61.
Recent insider activity shows 17 sales totaling $25.8 million over the last 90 days, with no buys. Dana Boyle, Chief Accounting Officer, and Jason Adair, Chief Business Officer, both sold shares on October 26, 2026. Congressional disclosures indicate three sales and one buy in the last 90 days. The stock printed 13 fresh 52-week highs and 4 fresh 52-week lows on November 10, 2026.
What To Watch
Investors will monitor the company’s presentation at the 2026 Jefferies Global Healthcare Conference. Management plans to provide updated 2027 guidance in early January as it evaluates demand following the litigation settlement.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LQDA by the numbers
The headlines behind the move
LQDA Maintained by BTIG -- Price Target Raised to $87.00
Liquidia (LQDA) Q3 2026 Earnings Call Transcript
Record October shipments and a widening prescriber base followed a costly settlement.
BTIG raises Liquidia stock price target to $87 on strong demand
BTIG raises Liquidia stock price target to $87 on strong demand
Liquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029
Liquidia Q3 net product sales rose 31% to $222.7 million, while management deferred 2027 guidance until early January as it tracks post-settlement demand.
Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q3 2026 Earnings Call November 10, 2026 8:30 AM ESTCompany ParticipantsJason Adair - Chief Business OfficerRoger Jeffs - CEO...
Liquidia price target raised to $87 from $70 at BTIG
Jefferies raises Liquidia stock price target to $62 on revenue growth
Jefferies raises Liquidia stock price target to $62 on revenue growth
More on LQDA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LQDA move explainers: 2026-11-12 · 2026-11-11 · 2026-11-10 · 2026-11-04 · 2026-10-15 · 2026-10-14 · 2026-10-08 · 2026-10-01 · 2026-09-30